Overview

A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)

Status:
Completed
Trial end date:
2015-03-09
Target enrollment:
Participant gender:
Summary
To evaluate the safety and pharmacokinetics (PK) of multiple doses of GWP42003-P compared with placebo in children with Dravet syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
GW Research Ltd
Treatments:
Cannabidiol
Pharmaceutical Solutions